Tango Therapeutics Files 8-K
Ticker: TNGX · Form: 8-K · Filed: Oct 23, 2025 · CIK: 1819133
Sentiment: neutral
Topics: sec-filing, operations, financials
TL;DR
Tango Therapeutics filed an 8-K on 10/23/25 covering operations and financials.
AI Summary
Tango Therapeutics, Inc. filed an 8-K on October 23, 2025, reporting on its results of operations and financial condition, as well as other events and financial statements. The filing does not contain specific financial figures or details about the 'other events' within the provided text.
Why It Matters
This 8-K filing indicates Tango Therapeutics is providing updates on its financial condition and operations to the SEC, which is standard for public companies.
Risk Assessment
Risk Level: low — This is a routine SEC filing reporting on financial condition and operations, with no immediate negative or positive indicators presented in the provided text.
Key Numbers
- 20251023 — Filing Date (Date of report and earliest event)
- 0001819133 — Central Index Key (Company identifier)
Key Players & Entities
- Tango Therapeutics, Inc. (company) — Registrant
- BCTG Acquisition Corp. (company) — Former company name
- 001-39485 (dollar_amount) — SEC File Number
- 201 Brookline Ave. (company) — Business Address
FAQ
What specific financial results or operational updates are detailed in this 8-K filing?
The provided text indicates the filing covers 'Results of Operations and Financial Condition' and 'Other Events' but does not include specific financial figures or details of these events.
When was Tango Therapeutics, Inc. formerly known as BCTG Acquisition Corp.?
The filing states the date of the name change from BCTG Acquisition Corp. to Tango Therapeutics, Inc. was July 23, 2020 (20200723).
What is Tango Therapeutics' principal executive office address?
The principal executive offices are located at 201 Brookline Ave., Suite 901, Boston, MA 02215.
What is the SEC file number for Tango Therapeutics, Inc.?
The SEC file number for Tango Therapeutics, Inc. is 001-39485.
What is the SIC code for Tango Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Tango Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 653 words · 3 min read · ~2 pages · Grade level 12.4 · Accepted 2025-10-23 07:04:40
Key Financial Figures
- $0.001 — ich registered Common stock, par value $0.001 per share TNGX The Nasdaq Global Ma
- $152.8 million — 2025, the Company estimates that it had $152.8 million of cash, cash equivalents and marketabl
Filing Documents
- d88744d8k.htm (8-K) — 27KB
- d88744dex991.htm (EX-99.1) — 27KB
- g88744ex99_1s10g1.jpg (GRAPHIC) — 72KB
- g88744ex99_1s11g1.jpg (GRAPHIC) — 58KB
- g88744ex99_1s12g1.jpg (GRAPHIC) — 68KB
- g88744ex99_1s13g1.jpg (GRAPHIC) — 88KB
- g88744ex99_1s14g1.jpg (GRAPHIC) — 59KB
- g88744ex99_1s15g1.jpg (GRAPHIC) — 86KB
- g88744ex99_1s16g1.jpg (GRAPHIC) — 55KB
- g88744ex99_1s17g1.jpg (GRAPHIC) — 59KB
- g88744ex99_1s18g1.jpg (GRAPHIC) — 66KB
- g88744ex99_1s19g1.jpg (GRAPHIC) — 86KB
- g88744ex99_1s1g1.jpg (GRAPHIC) — 46KB
- g88744ex99_1s20g1.jpg (GRAPHIC) — 86KB
- g88744ex99_1s2g1.jpg (GRAPHIC) — 240KB
- g88744ex99_1s3g1.jpg (GRAPHIC) — 77KB
- g88744ex99_1s4g1.jpg (GRAPHIC) — 37KB
- g88744ex99_1s5g1.jpg (GRAPHIC) — 76KB
- g88744ex99_1s6g1.jpg (GRAPHIC) — 107KB
- g88744ex99_1s7g1.jpg (GRAPHIC) — 50KB
- g88744ex99_1s8g1.jpg (GRAPHIC) — 66KB
- g88744ex99_1s9g1.jpg (GRAPHIC) — 74KB
- 0001193125-25-247658.txt ( ) — 2322KB
- tngx-20251023.xsd (EX-101.SCH) — 3KB
- tngx-20251023_lab.xml (EX-101.LAB) — 18KB
- tngx-20251023_pre.xml (EX-101.PRE) — 11KB
- d88744d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Corporate presentation of Tango Therapeutics, Inc. 104 Cover Page Interactive Data File (embedded within Inline XBRL document) Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TANGO THERAPEUTICS, INC. Dated: October 23, 2025 By: /s/ Daniella Beckman Name: Daniella Beckman Title: Chief Financial Officer